Literature DB >> 21761159

Risk factors for lymphedema in breast cancer survivors, the Iowa Women's Health Study.

Rehana L Ahmed1, Kathryn H Schmitz, Anna E Prizment, Aaron R Folsom.   

Abstract

Risk factors for lymphedema and related arm symptoms in breast cancer (BC) survivors have not been examined using a large prospective population-based cohort. The Iowa Women's Health Study (IWHS) collected self-reported data for diagnosed lymphedema in 2004, and data for cancer diagnosis, treatment, behavioral and health characteristics between 1986 and 2003. We studied 1,287 women, aged 55-69 at baseline, who developed unilateral BC: n = 104 (8%) with diagnosed lymphedema, n = 475 (37%) with arm symptoms but without diagnosed lymphedema, and n = 708 without lymphedema. Age- and multivariate-adjusted logistic regression models examined risk factors for lymphedema and related arm symptoms (OR [95% confidence interval]). The mean time between BC and the 2004 survey was 8.1 ± 5.0 (mean ± SD) years. After multivariate adjustment, the following cancer characteristics were positively associated with lymphedema: tumor stage (regional vs. in situ: 3.92 [1.61-9.54]), number of excised nodes (highest vs. lowest quintile: 3.52 [1.32-9.34], P (trend) = 0.003), tumor-positive nodes (yes vs. no 2.12 [1.19, 3.79]), and adjuvant chemotherapy (yes vs. no: 3.05 [1.75-5.30]). Several health characteristics were positively associated with lymphedema: baseline body mass index (highest vs. lowest tertile: 3.24 [1.70-6.21]), waist and hip circumference, and general health (fair/poor vs. excellent: 3.44 [1.30-9.06]). Positive associations with arm symptoms were number of excised nodes (highest vs. lowest quintile: 2.38 [1.41-4.03], P (trend) = 0.007), axillary radiation (yes vs. no: 1.72 [1.15-2.57]), and baseline general health (fair/poor vs. excellent: 4.27 [2.60-7.00]). In the IWHS, obesity, poorer general health, and markers of more advanced cancer were risk factors for lymphedema and related arm symptoms in BC survivors.

Entities:  

Mesh:

Year:  2011        PMID: 21761159      PMCID: PMC4091732          DOI: 10.1007/s10549-011-1667-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  37 in total

1.  Development and validation of a telephone questionnaire to characterize lymphedema in women treated for breast cancer.

Authors:  S A Norman; L T Miller; H B Erikson; M F Norman; R McCorkle
Journal:  Phys Ther       Date:  2001-06

2.  A randomized controlled trial of weight reduction as a treatment for breast cancer-related lymphedema.

Authors:  Clare Shaw; Peter Mortimer; Patricia A Judd
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

3.  Long-term morbidity following axillary dissection in breast cancer patients--clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors.

Authors:  T Kuehn; W Klauss; M Darsow; S Regele; F Flock; C Maiterth; R Dahlbender; I Wendt; R Kreienberg
Journal:  Breast Cancer Res Treat       Date:  2000-12       Impact factor: 4.872

4.  Lymphedema after sentinel lymphadenectomy for breast carcinoma.

Authors:  S F Sener; D J Winchester; C H Martz; J L Feldman; J A Cavanaugh; D P Winchester; B Weigel; K Bonnefoi; K Kirby; C Morehead
Journal:  Cancer       Date:  2001-08-15       Impact factor: 6.860

5.  Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study.

Authors:  B Clark; J Sitzia; W Harlow
Journal:  QJM       Date:  2005-04-08

6.  Age differences in post-breast cancer lymphedema signs and symptoms.

Authors:  Jane Armer; Mei R Fu
Journal:  Cancer Nurs       Date:  2005 May-Jun       Impact factor: 2.592

7.  Breast cancer-related lymphedema--what are the significant predictors and how they affect the severity of lymphedema?

Authors:  Atilla Soran; Gina D'Angelo; Mirsada Begovic; Figen Ardic; Ali Harlak; H Samuel Wieand; Victor G Vogel; Ronald R Johnson
Journal:  Breast J       Date:  2006 Nov-Dec       Impact factor: 2.431

8.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.

Authors:  Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

9.  The epidemiology of arm and hand swelling in premenopausal breast cancer survivors.

Authors:  Electra D Paskett; Michelle J Naughton; Thomas P McCoy; L Douglas Case; Jill M Abbott
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-04       Impact factor: 4.254

10.  Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study.

Authors:  Rehana L Ahmed; Anna Prizment; DeAnn Lazovich; Kathryn H Schmitz; Aaron R Folsom
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

View more
  55 in total

Review 1.  A systematic review of large-scale surveys of cancer survivors conducted in North America, 2000-2011.

Authors:  Catherine C Lerro; Kevin D Stein; Tenbroeck Smith; Katherine S Virgo
Journal:  J Cancer Surviv       Date:  2012-03-03       Impact factor: 4.442

Review 2.  Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity.

Authors:  Kathryn H Schmitz; Marian L Neuhouser; Tanya Agurs-Collins; Krista A Zanetti; Lisa Cadmus-Bertram; Lorraine T Dean; Bettina F Drake
Journal:  J Natl Cancer Inst       Date:  2013-08-29       Impact factor: 13.506

3.  Prescription and adherence to lymphedema self-care modalities among women with breast cancer-related lymphedema.

Authors:  Justin C Brown; Andrea L Cheville; Julia C Tchou; Susan R Harris; Kathryn H Schmitz
Journal:  Support Care Cancer       Date:  2013-09-07       Impact factor: 3.603

4.  Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer.

Authors:  Lauren S Jammallo; Cynthia L Miller; Marybeth Singer; Nora K Horick; Melissa N Skolny; Michelle C Specht; Jean O'Toole; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2013-11       Impact factor: 4.872

5.  Lymphedema: experience of a cohort of women with breast cancer followed for 4 years after diagnosis in Victoria, Australia.

Authors:  Robin J Bell; Penelope J Robinson; Raychel Barallon; Pamela Fradkin; Max Schwarz; Susan R Davis
Journal:  Support Care Cancer       Date:  2013-02-24       Impact factor: 3.603

Review 6.  Manual lymphatic drainage for lymphedema following breast cancer treatment.

Authors:  Jeanette Ezzo; Eric Manheimer; Margaret L McNeely; Doris M Howell; Robert Weiss; Karin I Johansson; Ting Bao; Linda Bily; Catherine M Tuppo; Anne F Williams; Didem Karadibak
Journal:  Cochrane Database Syst Rev       Date:  2015-05-21

7.  Patient compliance with a health care provider referral for an occupational therapy lymphedema consult.

Authors:  Sally A Dominick; Loki Natarajan; John P Pierce; Hala Madanat; Lisa Madlensky
Journal:  Support Care Cancer       Date:  2014-02-14       Impact factor: 3.603

8.  Treatment-related risk factors for arm lymphedema among long-term breast cancer survivors.

Authors:  Nandita Das; Richard N Baumgartner; Elizabeth C Riley; Christina M Pinkston; Dongyan Yang; Kathy B Baumgartner
Journal:  J Cancer Surviv       Date:  2015-04-26       Impact factor: 4.442

9.  Proactive approach to lymphedema risk reduction: a prospective study.

Authors:  Mei R Fu; Deborah Axelrod; Amber A Guth; Francis Cartwright; Zeyuan Qiu; Judith D Goldberg; June Kim; Joan Scagliola; Robin Kleinman; Judith Haber
Journal:  Ann Surg Oncol       Date:  2014-05-09       Impact factor: 5.344

10.  Race/ethnicity, genetic ancestry, and breast cancer-related lymphedema in the Pathways Study.

Authors:  Marilyn L Kwan; Song Yao; Valerie S Lee; Janise M Roh; Qianqian Zhu; Isaac J Ergas; Qian Liu; Yali Zhang; Susan E Kutner; Charles P Quesenberry; Christine B Ambrosone; Lawrence H Kushi
Journal:  Breast Cancer Res Treat       Date:  2016-07-22       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.